Clinical Trial Update: Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ifosfamide with and without paclitaxel in advanced, refractory, or recurrent cancer of the uterus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcoma
• Uterine Cancer

Drugs mentioned

• IFOSFAMIDE (IFOSFAMIDE)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Sarcoma | Phase 3 | Status: COMPLETED